Proteome Sciences Collaborating with CHDI on Proteomic Profiles of Huntington's Disease

Aug 20, 2012

|

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it will collaborate with CHDI Foundation on research into protein biomarkers for Huntington's disease.

Under the collaboration, the London-based company will use its Tandem Mass Tag reagents to develop mass spectrometry-based high density protein expression maps in cell lines carrying different levels of the CAG-repeat genetic alteration linked to Huntington's.

The work will be done at Proteome Sciences' ISO 9001:2008 certified facility in Frankfurt. Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

A Winning Diagnostic

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

Science in Africa Unevenly Funded

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

Not Enough Progress?

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

This Week in Science

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Featured White Papers

A Mammalian System for Antibody/Protein Library Screening

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Stroma Liquid Biopsy - Biomarkers of the Dysregulation of the Serum Proteome in Cancer

Cleanascite Lipid Removal & Clarification Reference Applications

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Main menu